What is Leerink Partnrs’ Forecast for LRMR FY2026 Earnings?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Stock analysts at Leerink Partnrs raised their FY2026 earnings estimates for shares of Larimar Therapeutics in a report issued on Monday, June 23rd. Leerink Partnrs analyst J. Park now anticipates that the company will post earnings of ($2.21) per share for the year, up from their previous forecast of ($2.61). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Leerink Partnrs also issued estimates for Larimar Therapeutics’ FY2027 earnings at ($1.82) EPS and FY2028 earnings at ($0.94) EPS.

Several other research firms also recently issued reports on LRMR. Robert W. Baird reduced their price target on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday, March 25th. Citigroup reaffirmed a “buy” rating on shares of Larimar Therapeutics in a report on Tuesday, March 25th. HC Wainwright lifted their price objective on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, March 25th. Wedbush cut their price objective on shares of Larimar Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Guggenheim reaffirmed a “buy” rating and set a $26.00 price objective on shares of Larimar Therapeutics in a report on Tuesday. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $18.50.

Larimar Therapeutics Trading Up 8.7%

NASDAQ LRMR opened at $3.25 on Thursday. The company has a fifty day simple moving average of $2.37 and a 200 day simple moving average of $2.96. Larimar Therapeutics has a 12-month low of $1.61 and a 12-month high of $11.20. The company has a market cap of $208.10 million, a P/E ratio of -2.18 and a beta of 0.79.

Larimar Therapeutics (NASDAQ:LRMR) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

Hedge Funds Weigh In On Larimar Therapeutics

A number of hedge funds have recently bought and sold shares of the company. ProShare Advisors LLC purchased a new position in shares of Larimar Therapeutics in the 4th quarter worth about $58,000. Janus Henderson Group PLC boosted its holdings in shares of Larimar Therapeutics by 15.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,443,286 shares of the company’s stock worth $24,936,000 after buying an additional 876,431 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Larimar Therapeutics by 23.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock worth $8,127,000 after buying an additional 399,123 shares during the last quarter. Alyeska Investment Group L.P. boosted its holdings in shares of Larimar Therapeutics by 38.6% in the 4th quarter. Alyeska Investment Group L.P. now owns 984,077 shares of the company’s stock worth $3,808,000 after buying an additional 273,920 shares during the last quarter. Finally, Blue Owl Capital Holdings LP boosted its holdings in shares of Larimar Therapeutics by 11.7% in the 4th quarter. Blue Owl Capital Holdings LP now owns 4,653,040 shares of the company’s stock worth $18,007,000 after buying an additional 486,211 shares during the last quarter. 91.92% of the stock is owned by hedge funds and other institutional investors.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.